JBRA Assist. Reprod. 2025;29(4):691-697
ORIGINAL ARTICLE
doi: 10.5935/1518-0557.20250157
Influence of infertility-associated autoantibodies and sexually transmitted infections on implantation success rates after ICSI
1EUROIMMUN Brasil. Cerâmica, São Caetano do Sul, São Paulo, Brazil
2Centro Universitário FMABC, Santo André, São Paulo, Brazil
3Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany
4IDEIA FÉRTIL Institute of Reproductive Health - Center for Studies in Genetics and Human Reproduction. Santo André, São Paulo, Brazil
CONFLICT OF INTERESTS
T. Hammes and J. Warnecke are employees of EUROIMMUN AG, a company that manufactures diagnostic tests and instruments. T. Hammes and J. Warnecke did not benefit from any potential or actual financial gain as a result of this publication. N. B. S. Bacarov, R. Hidalgo, A. C. Bernardo, C. Fideles, L. D. Garcia, and M. M. Soane are collaborators at EUROIMMUN Brazil - a subsidiary from EUROIMMUN AG. Like the other authors, they declare no potential or actual financial benefit related to this publication.
ABSTRACT
Objective: Preimplantation genetic testing improves rates of assisted reproductive technologies success by selecting euploid embryos, reducing implantation failures and miscarriages. However, some factors in women may also impact outcomes, though systematic studies on autoantibodies and implantation success are lacking. In this study, we determined the presence of specific autoantibodies related to infertility and specific antibodies to sexually transmitted infections pathogens among women undergoing intracytoplasmic sperm injection including preimplantation genetic testing and investigated their effect on implantation success.
Methods: Plasma samples from 86 women undergoing in vitro fertilization procedures by intracytoplasmic sperm injection and preimplantation genetic testing were tested for the presence of specific autoantibodies against the ovaries, placenta, uterus, and sperm as well as specific antibodies against Mycoplasma hominis, Ureaplasma urealyticum, Treponema pallidum, Chlamydia Trachomatis, Herpes simplex virus 1 and Herpes simplex virus 2. The prevalences of these antibodies were compared between women with successful versus unsuccessful implantation after embryo transfer.
Results: The prevalence of anti-Ureaplasma urealyticum antibodies was significantly higher (Fisher’s exact test, p=0.028) in women with unsuccessful implantation after intracytoplasmic sperm injection procedures (62.0%), compared to women with successful implantation (36.1%).
Conclusions: The results of this study indicate that a past infection with Ureaplasma urealyticum might lead to an increased risk for implantation failure after intracytoplasmic sperm injection procedures. Thus, the detection of IgG antibodies against Ureaplasma urealyticum could potentially be used in the future to identify women with an increased risk for implantation failure. However, our findings need to be confirmed in larger cohorts.
Keywords: infertility, in-vitro fertilization, sexually transmitted infections
INTRODUCTION
Infertility is a disease in which the effected patient is not able to establish a clinical pregnancy after a duration of 12 months of unprotected, regular sexual intercourse or if the patient’s capacity to reproduce is impaired (Zegers-Hochschild et al., 2017). Of couples within their reproductive ages, infertility is estimated to affect approximately 8 - 12% of couples worldwide (Vander Borght & Wyns, 2018). A broad variety of factors causing infertility has been described in the literature, including maternal or paternal age, endocrine dysfunctions, autoimmune diseases, anatomical abnormalities, genetic abnormalities, and infections affecting the male and female reproductive system (Yatsenko & Rajkovic, 2019). Approximately 30% of infertile couples are diagnosed with unexplained infertility, a condition in which no abnormalities in the female or male reproductive systems are identified (Guideline Group on Unexplained Infertility et al., 2023).
Assisted reproductive technologies (ART), such as in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), are used to treat infertility. Implantation of a fertilized egg into the uterus is a critical step during ART. The implantation success depends on multiple factors, for example on a competent blastocyst, receptive endometrium and successful crosstalk between the embryonic and maternal interfaces (Franasiak et al., 2021). When performing ICSI, in which a single sperm is directly injected into the unfertilized egg cell, preimplantation genetic testing (PGT) can be performed prior to embryo transfer to gain information on the genetic health of the embryos and subsequently select the most promising embryo for the transfer (Franasiak & Scott, 2017). Different PGT approaches are used in clinical practice, for example PGT for aneuploidy (PGT-A) or PGT for chromosomal structural rearrangements (PGT-SR) (ESHRE PGT Consortium Steering Committee et al., 2020). It has been shown that PGT can increase the success rate of ART by reducing the rates of implantation failure, miscarriage and congenital anomalies, especially in populations with advanced maternal age, where the aneuploidy rate is higher, or in cases of recurrent pregnancy loss (Varga et al., 2019; Greco et al., 2020; Morales, 2024). Despite the benefits of PGT, there is still controversy regarding the effectiveness of PGT in improving pregnancy success and live birth rates in all populations, especially in younger women and those with normal fertility (Morales, 2024).
Franasiak & Scott (2017) concluded that selection of an euploid blastocyst for implantation does not always lead to successful implantation. Several factors other than genetic abnormalities of the fetus may be associated with implantation failure, including maternal immunological and infectious factors (Franasiak & Scott, 2017).
The knowledge on mechanisms behind the development of autoimmune diseases is limited, but exposure to external factors (such as infections, environmental and hormonal factors) and the response of the immune system to these factors can influence the susceptibility of an individual to autoimmune diseases (Ngo et al., 2014). Some of the more common autoimmune diseases like Systemic Lupus Erythematosus (SLE), Type- 1-Diabetes or Hashimoto’s Thyroiditis are well-known causes of impaired fertility (Quintino-Moro et al., 2014; Lin et al., 2018; Stamm et al., 2022). In addition, a link between the presence of autoantibodies without manifestation of the associated autoimmune disease and infertility has been suggested previously (Carp et al., 2012). In this context, there is evidence that antibodies directed against various reproductive tissues and cells may also cause infertility. As an example, Kirshenbaum & Orvieto (2019) found that anti-ovarian antibodies are common amongst women suffering from premature ovarian insufficiency (POI). Also, there is an ongoing controversy, whether anti-sperm antibodies (ASA) play a role in infertility by impairing sperm motility, especially since these have been reported to be significantly increased in both infertile men and women (Nagaria et al., 2011; Gupta et al., 2022).
In addition to the influence of autoimmunity-related processes on fertility, Reese (2024) highlighted the importance of sexually transmitted infections (STIs) in reproductive health. Most active and past STIs can be diagnosed using a combination of tests for direct pathogen detection, like reverse transcription-polymerase chain reaction (RT-PCR) or serological tests; for example testing for pathogen-specific antibodies (Caruso et al., 2021). A considerable number of STIs, including those caused by Chlamydia trachomatis or Neisseria gonorrhoeae, frequently manifest without symptoms in women, which can lead to a delay in or missed diagnosis and onset of treatment (Van Gerwen et al., 2022). If left untreated, STIs can spread to the upper reproductive organs like the uterus, fallopian tubes or ovaries, leading to pelvic inflammatory disease (PID), which can ultimately result in infertility due to damage or scarring of the affected organs and tissues (Tsevat et al., 2017). In addition, it has been described that STIs can have a negative impact on IVF outcomes, with a higher rate of observed complications like implantation failures or miscarriages (Muller et al., 2015; Zhang et al., 2022).
Despite the continuously increasing know-how in the field of reproductive medicine, knowledge on the influence of the immune system on fertility remains incomplete, especially in the context of autoimmune processes involving reproductive organs. To improve fertility diagnostics and treatment success in the future, it is essential to gain further insights into the pathophysiology behind these mechanisms.
This study aimed to analyze the presence of anti-ovary, anti-placenta, anti-uterus, and anti-sperm antibodies as well as of antibodies directed against STI pathogens among women undergoing euploid embryo transfer after ICSI. Immunofluorescence tests (IIFT) and enzyme-linked immunosorbent assays (ELISA) were used to detect these antibodies, and the results were compared between women with successful versus unsuccessful implantation.
MATERIAL AND METHODS
We ran a cross-sectional study in which plasma samples were collected from 86 women undergoing fertility treatment at the Ideia Fértil Institute of Reproductive Health - Center for Studies in Genetics and Human Reproduction of ABC (Santo André, São Paulo, Brazil). The study was approved by the local Research Ethics Committee of the medical school of FMABC, São Paulo, Brazil (number 5.139.008).
Inclusion criteria: All participants were females, not older than 40 years of age and underwent ICSI and PGT-A or PGT-SR for euploid embryo selection at Ideia Fértil Institute. Only women who transferred embryos from fertilizations carried out with fresh sperm samples obtained by ejaculation were enrolled. Women gave their written informed consent.
Exclusion criteria: Women with signs of cervicitis at the time of sample collection, deep endometriosis, or persistent uterine pathogenesis were excluded. Women were excluded if the partner had severe male infertility. Women who chose to transfer more than one embryo, aneuploid embryos, or those with chromosomal mosaicism were excluded.
As there were no data investigating the prevalence of the used antibodies in the Brazilian population, we performed a pilot test in our sample considering ASA (anti sperm antibody). Then, a sample size calculation was performed with the assumption of a prevalence of ASA of 9,3% (standard error of 0,031) among infertile women. Selecting a confidence interval of 95%, a minimum of 80 participants was required to obtain statistically significant results (Miot, 2011).
Samples were collected only during cycles in which euploid blastocysts would be transferred. Blood collection was performed on the third day after the start of the luteal phase, which was supported by progesterone injection according to the treatment protocol. Blood samples were collected in a collection tube with EDTA (Sarstedt brand, model S-Monovette 2.6mL EDTA KE) at Ideia Fértil Institute. After collection, the samples were transferred and stored at -20°C until analysis.
The women were retrospectively divided into two groups depending on the outcome of implantation. Women with either a positive β-human chorionic gonadotropin (β-hCG) test or an ultrasound scan showing a live fetus four to six weeks after embryo transfer confirming successful implantation were assorted to the “successful implantation” group. Participants in the “unsuccessful implantation” group had a negative result on the β-hCG test or ultrasound without embryo and gestational sac.
Presence of IgG autoantibodies directed against tissue of the ovaries, placenta and uterus, as well as ASA was investigated by using the Infertility Mosaic 7 IVD kit (EUROIMMUN Medizinische Labordiagnostika AG, Germany). The plasma samples were processed and analyzed manually, according to manufacturer’s instructions for use.
Additionally, the presence of IgG antibodies against the following pathogens causing sexually transmitted infections (STI antibodies) was evaluated by ELISA commercial kit as described: Mycoplasma hominis and Ureaplasma urealyticum (Mycoplasma hominis, Ureaplasma urealyticum mosaic KIT, EUROIMMUN);Treponema pallidum [Treponema pallidum IgG (FTA-ABS) KIT, EUROIMMUN]; Herpes simplex virus 1 (HSV 1) and Herpes simplex virus 2 ( HSV-2) [Anti-HSV-1 (gC1) ELISA IgG and Anti-HSV-2 (gC2) ELISA IgG KIT, EUROIMMUN]; and Chlamydia trachomatis (Anti-Chlamydia trachomatis ELISA Advanced IgG KIT, EUROIMMUN).
Statistical analysis
For a descriptive data analysis, qualitative variables were presented by absolute and relative frequencies. To compare the qualitative variables, Fisher’s Exact test was used, and a confidence interval of 95% was adopted. The results are shown in Tables 1 and 2.
Table 1. Comparison of implantation success after embryo transfer and the number of positive and negative tests for antibodies against reproductive organs and spermatozoa.
Table 2. Comparison of implantation success after embryo transfer and the number of positive and negative tests for IgG STI antibodies.
The statistical analyses were performed using the Stata statistical program, version
14.0. (Stata, 2015). To demonstrate a statistically significant difference between the analyzed variables, the p-value had to be <0.05 in the Fisher’s Exact test. Borderline results were excluded for Fisher’s Exact test.
RESULTS
The women participating in the study were aged between 31 and 40 years old, with a median of 37 years old. All participants underwent ICSI, with exclusive transfer of euploid blastocysts. Of the 86 women, 65 had primary infertility, 14 had secondary infertility, four had had endometritis previously, two had uterine polyps surgically removed, and one had a monogenic disease.
36 of the 86 women (41.9%) had a successful implantation after embryo transfer and were assigned to the “successful implantation” group. The remaining 50 women (58.1%) did not have a successful implantation and were assigned to the “unsuccessful implantation” group. The median age of women in the “successful implantation” group was 36 years old (95% CI: 34-38), compared to 37 years old (95% CI: 36-39) in the “unsuccessful implantation” group. There was a statistically significant difference in the age of women between the two groups (independent t-test, p<0.05).
Considering the entire sample, we observed the frequency of 9.30% positive for ASA and 1.16% were positive for anti-ovarian antibodies. No anti-uterusor anti-placentaantibodies were detected. There was no statistically significant difference in the prevalence of ASA and anti-ovarian antibodies between women with successful versus unsuccessful implantation after embryo transfer (Fisher’s Exact test, Table 1).
Eight out of the 86 women were positive for anti-Treponema pallidum antibodies, 38 for anti-Mycoplasma hominis-antibodies; 43 for anti-Ureaplasma urealyticum antibodies; three for anti-Chlamydia trachomatis antibodies; 68 for anti-HSV-1 antibodies, and 19 for anti-HSV-2 antibodies. According to the results of the Fisher’s Exact test, there was a statistically significant (p=0.028) higher prevalence of anti-Ureaplasma urealyticum antibodies in the unsuccessful implantation group (62.0%), compared to the successful implantation group (36.1%) (Table 2). No statistically significant difference between the other STI antibodies was found in women with successful versus unsuccessful implantation (Table 2).
DISCUSSION
Treatment options and diagnostic methods for infertility have been continuously improving over the last decades, but still, in approximately 30% of patients with infertility, the underlying cause for the disease remains unclear, and implantation failure or miscarriages remain a challenge when using ART (Ma et al., 2022; Graham et al., 2023). In this study we aimed to analyze the effect of the presence of autoantibodies directed against reproductive tissues, ASA and STI antibodies on implantation rates after ICSI and PGT in 86 women, to gain further insights into the effect of the immune system on ART success.
Concerning autoantibodies directed against reproductive tissues and ASA, we found a prevalence of 9.30% for ASA and 1.16% for anti-ovarian antibodies. No antiuterus or anti-placenta antibodies were detected. The detected ASA prevalence is in line with previous published prevalences of ASA among infertile women, although some publications report a much higher prevalence of around 40% (Nagaria et al., 2011; Yasin et al., 2016; Ata et al., 2021). The prevalence of anti-ovarian antibodies was lower than what has previously been published; with prevalences of about 30% in infertile women (Luborsky et al., 1999). The difference in observed prevalences might be due to non-standardized testing for autoantibodies directed against components of the reproductive system. Thus, the obtained results and reported prevalences largely depend on the method used for the analysis.
There was no statistically significant difference in the ASA or anti-ovarian antibody prevalence between women with successful versus unsuccessful implantation after euploid embryo transfer; which implies that the presence of these antibodies does not increase the risk for implantation failure when transferring euploid embryos after ICSI. This is in line with previous findings, that as of today, there is no clear evidence that autoantibodies are directly causing implantation failure, except for a strong correlation of the presence of antiphospholipid antibodies and implantation failure (Bashiri et al., 2018). For ASA, this is also in line with the recommendations published in the most recent guideline on unexplained infertility by the European Society of Human Reproduction and Embryology (Guideline Group on Unexplained Infertility et al., 2023). In this guideline, ASA testing in serum is not recommended in the diagnostic workup of infertility in women although the prevalence of ASA seems to be higher in infertile women compared to the general population, due to a lack of evidence that the test result would influence the decision on an outcome of an applied personalized treatment regimen. A similar statement can be found regarding anti-ovarian antibody testing in the new ESHRE guideline for the management of POI, in this guideline it is noted that the prevalence of anti-ovarian antibodies seems to be higher in patients with POI, but due to a lack in evidence regarding the clinical relevance and impact on treatment decisions, routine testing for these antibodies is not recommended (Luborsky et al., 2000; Panay et al., 2024). Thus, further research on the impact of autoantibodies directed against reproductive tissues and ASA on female fertility is needed to assess, whether testing for these antibodies in the workup of infertility would be beneficial to ultimately improve personalized ART treatment regimens.
Regarding the analysis of STI antibodies amongst all women included in the study, the most prevalent ones were antibodies against HSV-1 with a prevalence of 91.89%, followed by antibodies against Ureaplasma urealyticum (51.16%), Mycoplasma hominis (44.19%), HSV-2 (25.33%), Treponema pallidum (9.30%) and Chlamydia trachomatis (3.85%). The prevalences of antibodies against HSV-1, HSV-2 and Treponema pallidum were in the range of what has been observed in general population studies in Brazil (Clemens & Farhat, 2010; Warnecke et al., 2020). The detected prevalence of antibodies against Chlamydia trachomatis was lower compared to previously published data for the general population and for women with infertility (Claman et al., 1997; Warnecke et al., 2020). This might be the result of the ELISA test that was used for the analysis, which has been improved to reduce cross-reactivity of antibodies against other Chlamydia subspecies, especially Chlamydia pneumoniae which occurs in much higher incidence rates compared to Chlamydia trachomatis, thus reducing the number of false positive results. The relatively high prevalences for antibodies against Ureaplasma urealyticum and Mycoplasma hominis is in line with previous publications on the prevalence of active infections with these pathogens Rodrigues et al. (2011). In this context, it has been observed that when analyzing antibodies against Ureaplasma and Mycoplasma subspecies, cross-reactivity is a possibility that must be considered when interpreting the results. We did, however, observe a significantly higher prevalence of antibodies against Ureaplasma urealyticum in the unsuccessful implantation group (62.0%) compared to the successful implantation group (36.1%). In a meta-analysis, Tantengco et al. (2021) observed that female infertility was significantly associated with genital infections with Mycoplasma genitalium, Mycoplasma hominis, and Ureaplasma urealyticum. The same study demonstrated that inflammation caused by these pathogens could result in scarring, cell death, and tubal occlusion - which can be a potential explanation of how these organisms may contribute to female infertility. Our results suggest that a past infection with Ureaplasma urealyticum might not only increase the risk for infertility, but also increase the risk for implantation failure when transferring euploid embryos in ICSI procedures. Previous studies have shown that an infection with Ureaplasma urealyticum can cause chronic endometritis, a chronic lowgrade inflammation of the endometrium, that seems to be associated with recurrent implantation failure (Johnston-MacAnanny et al., 2010; Franasiak et al., 2018). This might be a possible explanation for our findings and supports the findings of previous research recommending that infections should be considered in the diagnostic workup of recurrent implantation failure (Ma et al., 2022; ESHRE Working Group on Recurrent Implantation Failure et al., 2023). We did not find evidence that a past infection with any of the other investigated STIs has an impact on implantation rates, although this has been suggested by others (Wang et al., 2015; Zhang et al., 2022). This might be due to the relatively small cohort investigated in our study. More studies are needed to confirm these hypotheses and for determining the mechanisms behind the influence of previous infections with STIs on implantation rates in ART.
The evidence of this study is limited by the number of women included in this study. Thus, our results needed to be confirmed in larger cohorts. Also, women in the “unsuccessful implantation” group were significantly older than women in the “successful implantation” group and maternal age has been shown to impact implantation rates (Ma et al., 2022). Therefore, our findings need to be confirmed in studies investigating cohorts of women that are of the same age or that even age-matched patients. Future studies on the influence of the immune system on ART outcome should also investigate different ART techniques and use additional outcome variables, such as number of oocytes retrieved after ovarian stimulation, occurrence of recurrent implantation failure or cumulative live birth to be able to determine which step within a certain ART procedure might be affected by which immunological feature.
CONCLUSION
Successful implantation after embryo transfer is one of the most critical steps in ART. Even when transferring euploid embryos, implantation failure remains to be a common complication. Present evidence suggests that a previous infection with Ureaplasma urealyticum might lead to an increased risk for implantation failure in ART procedures. Thus, the detection of IgG antibodies against Ureaplasma urealyticum could potentially be used in the future to identify women with an increased risk for implantation failure, however, targeted treatment options would be required to improve ART success based on the respective test result.
AUTHOR CONTRIBUTIONS
N. B. S. Bacarov:
• Conceptualization: Designed the research;
• Data Curation: Collected the data;
• Formal Analysis: Performed the statistical analysis;
• Writing – Original Draft: Wrote the first draft of the paper.
T. Hammes:
• Formal Analysis: Evaluated data analysis, statistics, and results interpretation;
• Writing – Review & Editing: Revised the manuscript.
J. M. Warncke:
• Writing – Review & Editing: Reviewed the final manuscript version.
D. M. Christofolini:
• Supervision: Guided the entire execution of the work;
• Formal Analysis: Provided input on data analysis
• Writing – Review & Editing: Contributed to the preparation of the paper.
R. Hidalgo, A. C. Bernardo, C. Fideles, L. D. Garcia:
• Investigation: Contributed to the laboratory analyses;
• Writing – Review & Editing: Reviewed the manuscript.
C. P. Barbosa and M.M. Soane:
• Supervision: Provided technical guidance;
• Writing – Review & Editing: Reviewed the manuscript version.
Funding
The authors received collaboration with in-vitro diagnostic kits for research from the Company EUROIMMUN Brazil. EUROIMMUN Medizinische Labordiagnostika AG sponsored the in-vitro diagnostic test-kits required for this study following the recommendations of the updated Good Publication Practice (GPP3) guideline.
REFERENCES
Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;16:121. PMID: 30518389 DOI: 10.1186/s12958-018-0414-2 Medline
Carp HJA, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun. 2012;38:J266-74. PMID: 22284905 DOI: 10.1016/j.jaut.2011.11.016 Medline
Caruso G, Giammanco A, Virruso R, Fasciana T. Current and Future Trends in the Laboratory Diagnosis of Sexually Transmitted Infections. Int J Environ Res Public Health. 2021;18:1038. PMID: 33503917 DOI: 10.3390/ijerph18031038 Medline
Claman P, Honey L, Peeling RW, Jessamine P, Toye B. The presence of serum antibody to the chlamydial heat shock protein (CHSP60) as a diagnostic test for tubal factor infertility. Fertil Steril. 1997;67:501-4. PMID: 9091338 DOI: 10.1016/S0015-0282(97)80077-5 Medline
Clemens SA, Farhat CK. Seroprevalence of herpes simplex 1-2 antibodies in Brazil. Rev Saude Publica. 2010;44:726-34. PMID: 20676563 DOI: 10.1590/s0034-89102010000400017 Medline
ESHRE PGT Consortium Steering Committee; Carvalho F, Coonen E, Goossens V, Kokkali G, Rubio C, Meijer-Hoogeveen M, Moutou C, Vermeulen N, De Rycke M. ESHRE PGT Consortium good practice recommendations for the organisation of PGT. Hum Reprod Open. 2020;2020:hoaa021. PMID: 32524036 DOI: 10.1093/hropen/hoaa021 Medline
ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de Los Santos MJ, Griesinger G, Lainas G, Le Clef N, McLernon DJ, Montjean D, Toth B, Vermeulen N, Macklon N. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023:hoad023. PMID: 37332387 DOI: 10.1093/hropen/hoad023 Medline
Franasiak JM, Alecsandru D, Forman EJ, Gemmell LC, Goldberg JM, Llarena N, Margolis C, Laven J, Schoenmakers S, Seli E. A review of the pathophysiology of recurrent implantation failure. Fertil Steril. 2021;116:1436-48. PMID: 34674825 DOI: 10.1016/j.fertnstert.2021.09.014 Medline
Franasiak JM, Scott RT. Contribution of immunology to implantation failure of euploid embryos. Fertil Steril. 2017;107:1279-83. PMID: 28501368 DOI: 10.1016/j.fertnstert.2017.04.019 Medline
Graham ME, Jelin A, Hoon AH Jr, Wilms Floet AM, Levey E, Graham EM. Assisted reproductive technology: Shortand long-term outcomes. Dev Med Child Neurol. 2023;65:38-49. PMID: 35851656 DOI: 10.1111/dmcn.15332 Medline
Greco E, Litwicka K, Minasi MG, Cursio E, Greco PF, Barillari P. Preimplantation Genetic Testing: Where We Are Today. Int J Mol Sci. 2020;21:4381. PMID: 32575575 DOI: 10.3390/ijms21124381 Medline
Guideline Group on Unexplained Infertility; Romualdi D, Ata B, Bhattacharya S, Bosch E, Costello M, Gersak K, Homburg R, Mincheva M, Norman RJ, Piltonen T, Dos Santos-Ribeiro S, Scicluna D, Somers S, Sunkara SK, Verhoeve HR, Le Clef N. Evidence-based guideline: unexplained infertility†. Hum Reprod. 2023;38:1881-90. PMID: 37599566 DOI: 10.1093/humrep/dead150 Medline
Gupta S, Sharma R, Agarwal A, Boitrelle F, Finelli R, Farkouh A, Saleh R, Abdel-Meguid TA, Gül M, Zilaitiene B, Ko E, Rambhatla A, Zini A, Leisegang K, Kuroda S, Henkel R, Cannarella R, Palani A, Cho CL, Ho CCK, et al. Antisperm Antibody Testing: A Comprehensive Review of Its Role in the Management of Immunological Male Infertility and Results of a Global Survey of Clinical Practices. World J Mens Health. 2022;40:380-98. PMID: 35021297 DOI: 10.5534/wjmh.210164 Medline
Johnston-MacAnanny EB, Hartnett J, Engmann LL, Nulsen JC, Sanders MM, Benadiva CA. Chronic endometritis is a frequent finding in women with recurrent implantation failure after in vitro fertilization. Fertil Steril. 2010;93:437-41. PMID: 19217098 DOI: 10.1016/j.fertnstert.2008.12.131 Medline
Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019;36:2207-15. PMID: 31440958 DOI: 10.1007/s10815-019-01572-0 Medline
Lin YH, Chen KJ, Peng YS, Chen PC, Yang YH. Type 1 diabetes impairs female fertility even before it is diagnosed. Diabetes Res Clin Pract. 2018;143:151-8. PMID: 30003941 DOI: 10.1016/j.diabres.2018.07.010 Medline
Luborsky J, Llanes B, Davies S, Binor Z, Radwanska E, Pong R. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Clin Immunol. 1999;90:368-74. PMID: 10075866 DOI: 10.1006/clim.1998.4661 Medline
Luborsky J, Llanes B, Roussev R, Coulam C. Ovarian antibodies, FSH and inhibin B: independent markers associated with unexplained infertility. Hum Reprod. 2000;15:1046-51. PMID: 10783349 DOI: 10.1093/humrep/15.5.1046 Medline
Ma J, Gao W, Li D. Recurrent implantation failure: A comprehensive summary from etiology to treatment. Front Endocrinol. 2022;13:1061766. PMID: 36686483 DOI: 10.3389/fendo.2022.1061766 Medline
Morales C. Current Applications and Controversies in Preimplantation Genetic Testing for Aneuploidies (PGT-A) in In Vitro Fertilization. Reprod Sci. 2024;31:66-80. PMID: 37515717 DOI: 10.1007/s43032-023-01301-0 Medline
Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35:347-69. PMID: 24793874 DOI: 10.1016/j.yfrne.2014.04.004 Medline
Quintino-Moro A, Zantut-Wittmann DE, Tambascia M, Machado H da C, Fernandes A. High Prevalence of Infertility among Women with Graves’ Disease and Hashimoto’s Thyroiditis. Int J Endocrinol. 2014;2014:982705. PMID: 24678319 DOI: 10.1155/2014/982705 Medline
Reese PC. STIs During Pregnancy. Am Fam Physician. 2024;109:10-2. PMID: 38227864 Medline
Rodrigues MM, Fernandes PÁ, Haddad JP, Paiva MC, Souza Mdo C, Andrade TC, Fernandes AP. Frequency of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis and Ureaplasma species in cervical samples. J Obstet Gynaecol. 2011;31:237-41. PMID: 21417648 DOI: 10.3109/01443615.2010.548880 Medline
Stamm B, Barbhaiya M, Siegel C, Lieber S, Lockshin M, Sammaritano L. Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology. Lupus Sci Med. 2022;9:e000840. PMID: 36600642 DOI: 10.1136/lupus-2022-000840 Medline
Tantengco OAG, de Castro Silva M, Velayo CL. The role of genital mycoplasma infection in female infertility: A systematic review and meta-analysis. Am J Reprod Immunol. 2021;85:e13390. PMID: 33417733 DOI: 10.1111/aji.13390 Medline
Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2017;216:1-9. PMID: 28007229 DOI: 10.1016/j.ajog.2016.08.008 Medline
Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nat Microbiol. 2022;7:1116-26. PMID: 35918418 DOI: 10.1038/s41564-022-01177-x Medline
Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology. Clin Biochem. 2018;62:2-10. PMID: 29555319 DOI: 10.1016/j.clinbiochem.2018.03.012 Medline
Varga K, Tóth N, Bogár ÉB, Csontos L, Szabó K, Debreceni D, Margittai É, Csenki M, Vereczkey A. The demise of preimplantation genetic testing for aneuploidy (PGT-A) in Hungary and its effect on patient care. Eur J Med Genet. 2019;62:103669. PMID: 31082515 DOI: 10.1016/j.ejmg.2019.05.008 Medline
Wang J, Zhao X, Yuan P, Fang T, Ouyang N, Li R, Ou S, Wang W. Clinical Outcomes of In Vitro Fertilization among Chinese Infertile Couples Treated for Syphilis Infection. PLoS One. 2015;10:e0133726. PMID: 26208116 DOI: 10.1371/journal.pone.0133726 Medline
Warnecke JM, Pollmann M, Borchardt-Lohölter V, Moreira-Soto A, Kaya S, Sener AG, Gómez-Guzmán E, Figueroa-Hernández L, Li W, Li F, Buska K, Zakaszewska K, Ziolkowska K, Janz J, Ott A, Scheper T, Meyer W. Seroprevalences of antibodies against ToRCH infectious pathogens in women of childbearing age residing in Brazil, Mexico, Germany, Poland, Turkey and China. Epidemiol Infect. 2020;148:e271. PMID: 33124529 DOI: 10.1017/S0950268820002629 Medline
Yasin AL, Yasin AL, Basha WS. The Epidemiology of Anti-Sperm Antibodies Among Couples with Unexplained Infertility in North West Bank, Palestine. J Clin Diagn Res. 2016;10:QC01-3. PMID: 27134944 DOI: 10.7860/JCDR/2016/15788.7380 Medline
Yatsenko SA, Rajkovic A. Genetics of human female infertility†. Biol Reprod. 2019;101:549-66. PMID: 31077289 DOI: 10.1093/biolre/ioz084 Medline
Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, Rienzi L, Sunde A, Schmidt L, Cooke ID, Simpson JL, van der Poel S. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod. 2017;32:1786-801. PMID: 29117321 DOI: 10.1093/humrep/dex234 Medline
Zhang D, Wang Z, Hu X, Ma C, Ma Y, Xu Y. Effect of previous Chlamydia Trachomatis infection on the outcomes of ivf/icsi treatment: a retrospective study. BMC Pregnancy Childbirth. 2022;22:305. PMID: 35399086 DOI: 10.1186/s12884-022-04624-z Medline